Benzinga

España
Italia
대한민국
日本
Français
Benzinga Edge
Benzinga Research
Benzinga Pro

  • Get Benzinga Pro
  • Data & APIs
  • Events
  • Premarket
  • Advertise
Contribute
España
Italia
대한민국
日本
Français

Benzinga

  • Premium Services
  • Financial News
    Latest
    Earnings
    Guidance
    Dividends
    M&A
    Buybacks
    Interviews
    Management
    Offerings
    IPOs
    Insider Trades
    Biotech/FDA
    Politics
    Healthcare
    Small-Cap
  • Markets
    Pre-Market
    After Hours
    Movers
    ETFs
    Options
    Cryptocurrency
    Commodities
    Bonds
    Futures
    Mining
    Real Estate
    Volatility
  • Ratings
    Analyst Color
    Downgrades
    Upgrades
    Initiations
    Price Target
  • Investing Ideas
    Trade Ideas
    Long Ideas
    Short Ideas
    Technicals
    Analyst Ratings
    Analyst Color
    Latest Rumors
    Whisper Index
    Stock of the Day
    Best Stocks & ETFs
    Best Penny Stocks
    Best S&P 500 ETFs
    Best Swing Trade Stocks
    Best Blue Chip Stocks
    Best High-Volume Penny Stocks
    Best Small Cap ETFs
    Best Stocks to Day Trade
    Best REITs
  • Money
    Investing
    Cryptocurrency
    Mortgage
    Insurance
    Yield
    Personal Finance
    Forex
    Startup Investing
    Real Estate Investing
    Prop Trading
    Credit Cards
    Stock Brokers
Research
My Stocks
Tools
Free Benzinga Pro Trial
Calendars
Analyst Ratings Calendar
Conference Call Calendar
Dividend Calendar
Earnings Calendar
Economic Calendar
FDA Calendar
Guidance Calendar
IPO Calendar
M&A Calendar
Unusual Options Activity Calendar
SPAC Calendar
Stock Split Calendar
Trade Ideas
Stock Reports
Insider Trades
Trade Idea Feed
Analyst Ratings
Unusual Options Activity
Heatmaps
Free Newsletter
Government Trades
Perfect Stock Portfolio
Easy Income Portfolio
Short Interest
Most Shorted
Largest Increase
Largest Decrease
Calculators
Margin Calculator
Forex Profit Calculator
100x Options Profit Calculator
Screeners
Stock Screener
Top Momentum Stocks
Top Quality Stocks
Top Value Stocks
Top Growth Stocks
Compare Best Stocks
Best Momentum Stocks
Best Quality Stocks
Best Value Stocks
Best Growth Stocks
Connect With Us
facebookinstagramlinkedintwitteryoutubeblueskymastodon
About Benzinga
  • About Us
  • Careers
  • Advertise
  • Contact Us
Market Resources
  • Advanced Stock Screener Tools
  • Options Trading Chain Analysis
  • Comprehensive Earnings Calendar
  • Dividend Investor Calendar and Alerts
  • Economic Calendar and Market Events
  • IPO Calendar and New Listings
  • Market Outlook and Analysis
  • Wall Street Analyst Ratings and Targets
Trading Tools & Education
  • Benzinga Pro Trading Platform
  • Options Trading Strategies and News
  • Stock Market Trading Ideas and Analysis
  • Technical Analysis Charts and Indicators
  • Fundamental Analysis and Valuation
  • Day Trading Guides and Strategies
  • Live Investor Events
  • Pre-market Stock Analysis and News
  • Cryptocurrency Market Analysis and News
Ring the Bell

A newsletter built for market enthusiasts by market enthusiasts. Top stories, top movers, and trade ideas delivered to your inbox every weekday before and after the market closes.

  • Terms & Conditions
  • Do Not Sell My Personal Data/Privacy Policy
  • Disclaimer
  • Service Status
  • Sitemap
© 2026 Benzinga | All Rights Reserved
October 13, 2021 6:29 AM 1 min read

Cramer Recommends To Hold Doximity, Avoid This Industry And Buy This Stock

by Craig Jones Benzinga Staff Writer
Follow
FlipboardIcon version of the Flipboard logo

On CNBC’s “Mad Money Lightning Round," Jim Cramer said that although Doximity Inc (NYSE:DOCS) was a great company, it’s the kind of stock “that people have turned on.” He recommended holding Doximity for the long run, noting it's “how you make money.”

People are not buying Abbott Laboratories (NYSE:ABT) but are purchasing its rapid COVID-19 test, BinaxNOW, Cramer said, adding that COVID was going to be here for a long time. Although BinaxNOW’s preannouncement wasn't good, the pharma major has got “so many other things going for it.”

Cramer pointed out that Abbott wasn't a BinaxNOW story. He has liked the company for several years.

See Also: A Peek Into The Markets: US Stock Futures Gain Ahead Of CPI, Fed Minutes

Tilray Inc (NASDAQ:TLRY) is run by Irwin Simon, who used to be the CEO at Hain Celestial Group Inc (NASDAQ:HAIN). While saying he liked Simon very much, the "Mad Money" host commented that he didn’t like the cannabis industry. He does like the industrial real estate segment of the industry, but that’s a REIT.

Cramer noted that recruitment companies are very important in the current environment. Although Upwork Inc (NASDAQ:UPWK) has rallied, it could go higher, he added.

Market News and Data brought to you by Benzinga APIs

© 2026 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

To add Benzinga News as your preferred source on Google, click here.


Posted In:
Long IdeasMediaTrading IdeasCNBCJim Cramer
ABT Logo
ABTAbbott Laboratories
$112.65-%
Overview
DOCS Logo
DOCSDoximity Inc
$26.00-%
HAIN Logo
HAINThe Hain Celestial Group Inc
$0.6800-%
TLRY Logo
TLRYTilray Brands Inc
$7.27-%
UPWK Logo
UPWKUpwork Inc
$13.27-%
ABT Logo
ABTAbbott Laboratories
$112.65-%
Overview
DOCS Logo
DOCSDoximity Inc
$26.00-%
HAIN Logo
HAINThe Hain Celestial Group Inc
$0.6800-%
TLRY Logo
TLRYTilray Brands Inc
$7.27-%
UPWK Logo
UPWKUpwork Inc
$13.27-%
Comments
Loading...